RxDoctor Payments Data

Ayni Sharif, PA

Physician Assistant · Richmond, VANPI 1174853576

Payments from drug & device makers

$4,244in general payments, 2019–2025

Across 301 payments — averaging $14.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • AbbVie$728
  • Arbor Pharmaceuticals, Inc.$596
  • Collegium Pharmaceutical, Inc.$467
  • Scilex Pharmaceuticals Inc.$203
  • Averitas Pharma Inc.$151
  • plus $877 from 13 others

What the payments were for

  • Food & beverage$4,244100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,244 in reported general payments places this provider in the 90th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$62,299
Medicare patients
89
Services billed
754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl36$32,471
Nurtec OdtRimegepant Sulfate15$27,933
Xtampza ErOxycodone Myristate39$21,729
HorizantGabapentin Enacarbil11$9,562
Oxycodone Hcl412$9,062
Lidocaine67$8,577
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen230$7,044
Naloxone Hcl85$5,877
MovantikNaloxegol Oxalate12$4,781
Diclofenac Sodium76$4,767
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen159$3,632
OxycontinOxycodone Hcl12$3,469
Gabapentin280$2,883
Fentanyl28$2,259
Morphine Sulfate ErMorphine Sulfate71$1,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$467$54,19975 claims
PfizerNurtec Odt$119$27,93315 claims
Arbor Pharmaceuticals, Inc.Horizant$596$9,56211 claims
Redhill Biopharma Inc.Movantik$95$4,78112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →